- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03223389
Fat Metabolites and Gut Hormones
24. juli 2017 opdateret af: Christoffer Martinussen, Hvidovre University Hospital
Effects of Fat Metabolites on Gut Hormone Secretion After Gastric Bypass Surgery
To investigate the effects of different fat metabolites on gut hormone secretion in gastric bypass operated subjects and BMI-matched controls.
Studieoversigt
Status
Ukendt
Intervention / Behandling
Detaljeret beskrivelse
Dietary triglycerides are hydrolyzed during digestion to two fatty acids and one 2-monoacyl glycerol.
The study will investigate the effects of these different fat components on gut hormone secretion in gastric bypass operated patients and non-operated BMI-matched controls.
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
20
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Hvidovre, Danmark, 2650
- Dept. of Endocrinology
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 70 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Gastric bypass operated patients:
Inclusion Criteria:
- Uncomplicated gastric bypass surgery performed minimum 12 months prior to study
Exclusion Criteria:
- Type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery
- Pregnancy or breastfeeding
- Haemoglobin levels below 6,5 mM
- Gall bladder removal
Healthy control subjects:
Exclusion Criteria:
- Bariatric surgery or complicated upper abdominal surgery
- Gall bladder removal
- Pregnancy or breastfeeding
- Haemoglobin levels below 6,5 mM
- Co-morbidities or medicine significantly affecting glucose metabolism or appetite regulation
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: 10 gastric bypass operated patients
3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
|
Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
|
|
Eksperimentel: 10 healthy control subjects
3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
|
Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Within group difference in glucagon-like peptide-1 (GLP-1) secretion (evaluated by AUC above basal).
Tidsramme: 0-240 min following fat ingestion.
|
Comparison of the GLP-1 responses (evaluated by AUC above basal) induced by the different oils.
|
0-240 min following fat ingestion.
|
|
Within group difference in Gastric Inhibitory Peptide (GIP) secretion (evaluated by AUC above basal).
Tidsramme: 0-240 min following fat ingestion.
|
Comparison of the GIP responses (evaluated by AUC above basal) induced by the different oils.
|
0-240 min following fat ingestion.
|
|
Within group difference in cholecystokinin (CCK) secretion (evaluated by AUC above basal).
Tidsramme: 0-240 min following fat ingestion.
|
Comparison of the CCK responses (evaluated by AUC above basal) induced by the different oils.
|
0-240 min following fat ingestion.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Between group comparison of GLP-1 secretion (evaluated by AUC above basal).
Tidsramme: 0-240 min following fat ingestion.
|
GLP-1 secretion (evaluated by AUC above basal) in gastric bypass operated patients compared to BMI-matched control subjects for each of the oils.
|
0-240 min following fat ingestion.
|
|
Between group comparison of GIP secretion (evaluated by AUC above basal).
Tidsramme: 0-240 min following fat ingestion.
|
GIP secretion (evaluated by AUC above basal) in gastric bypass operated patients compared to BMI-matched control subjects for each of the oils.
|
0-240 min following fat ingestion.
|
|
Between group comparison of CCK secretion (evaluated by AUC above basal).
Tidsramme: 0-240 min following fat ingestion.
|
GIP secretion (evaluated by AUC above basal) in gastric bypass operated patients compared to BMI-matched control subjects for each of the oils.
|
0-240 min following fat ingestion.
|
|
Responses (evaluated by AUC above basal) of insulin within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Responses (evaluated by AUC above basal) of C-peptide within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Responses (evaluated by AUC above basal) of peptide YY (PYY) within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Responses (evaluated by AUC above basal) of oxyntomodulin within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Responses (evaluated by AUC above basal) of glucagon within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Responses (evaluated by AUC above basal) of bile acids within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Responses (evaluated by AUC above basal) of fibroblast growth factor 19 (FGF-19) within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Responses (evaluated by AUC above basal) of lipid metabolites (triglyceride, cholesterol, fatty acids) within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Responses (evaluated by AUC above basal) of neurotensin within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Responses (evaluated by AUC above basal) of glucose within and between groups.
Tidsramme: 0-240 min following fat ingestion.
|
0-240 min following fat ingestion.
|
|
|
Between group comparison of differences in GLP-1 secretion (evaluated by AUC above basal).
Tidsramme: 0-240 min following fat ingestion.
|
Differences in GLP-1 secretion (evaluated by AUC above basal) induced by the different oils in gastric bypass operated patients compared with differences in BMI-matched control subjects.
|
0-240 min following fat ingestion.
|
|
Between group comparison of differences in GIP secretion (evaluated by AUC above basal).
Tidsramme: 0-240 min following fat ingestion.
|
Differences in GIP secretion (evaluated by AUC above basal) induced by the different oils in gastric bypass operated patients compared with differences in BMI-matched control subjects.
|
0-240 min following fat ingestion.
|
|
Between group comparison of differences in CCK secretion (evaluated by AUC above basal).
Tidsramme: 0-240 min following fat ingestion.
|
Differences in CCK secretion (evaluated by AUC above basal) induced by the different oils in gastric bypass operated patients compared with differences in BMI-matched control subjects.
|
0-240 min following fat ingestion.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Forventet)
7. august 2017
Primær færdiggørelse (Forventet)
1. december 2018
Studieafslutning (Forventet)
1. december 2018
Datoer for studieregistrering
Først indsendt
18. juli 2017
Først indsendt, der opfyldte QC-kriterier
18. juli 2017
Først opslået (Faktiske)
21. juli 2017
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
26. juli 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
24. juli 2017
Sidst verificeret
1. juli 2017
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CM-FAT-17
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 2 diabetes
-
Jin-Hee AhnAsan Medical CenterUkendtHER-2-genamplifikation | HER-2 Protein Overekspression
-
The University of Tennessee, KnoxvilleAfsluttetMatematiklærere (2-8 klassetrin) | Matematikstuderende (2-8 klassetrin)Forenede Stater
-
Instituto Nacional de Ciencias Medicas y Nutricion...Aktiv, ikke rekrutterende
-
Endogenex, Inc.Ikke rekrutterer endnuDiabetes mellitus, type 2 | Diabetes | Type 2 diabetes | Type 2 diabetes mellitus (T2DM) | Type 2 Diabetes
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.UkendtSolid tumor | HER-2-genamplifikation | HER2 genmutation | HER-2 Protein OverekspressionKina
-
PowderMedAfsluttet
-
University of North Carolina, Chapel HillAmerican Heart AssociationRekrutteringType 2 diabetes | Ernæring | Diabetes type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes uddannelseForenede Stater
-
Embecta Corp.Jaeb Center for Health ResearchTrukket tilbageType 2 diabetes | Type 2 diabetes mellitus (T2DM) | T2DM (Type 2 Diabetes Mellitus) | T2D | T2DM | Type 2 DM | T2DM med utilstrækkelig glykæmisk kontrolForenede Stater
-
Beijing HospitalRekrutteringType 2 diabetespatienter | T2DM (Type 2 Diabetes Mellitus) | T2DMKina
-
Kaiser PermanenteThe Permanente Medical GroupTilmelding efter invitationType 2 diabetes | Type 2 diabetes mellitus (T2DM) | Type 2-diabetes (T2D)Forenede Stater
Kliniske forsøg med C-8 dietary oil
-
The Second Affiliated Hospital of Chongqing Medical...Rekruttering
-
Bactolife A/SRekrutteringClostridioides Difficile Infektion GentagelseForenede Stater
-
Kowa Research Institute, Inc.Afsluttet
-
University of Michigan Rogel Cancer CenterAktiv, ikke rekrutterendeAdenocarcinom i bugspytkirtlen | Pancreas neuroendokrin tumor | Pancreas neuroendokrint karcinom | Adenosquamøst karcinom | Gastrointestinal neuroendokrin tumor | Gastrointestinal neuroendokrin karcinom | Neuroendokrint prostatakarcinomForenede Stater
-
Weill Medical College of Cornell UniversityAfsluttet
-
A-Spine Asia Co., Ltd.RekrutteringTrauma | Skoliose | Degenerativ diskussygdom | Svulst | Stenose | Kyphose | Deformitet | Pseudoartrose af rygsøjlenTaiwan
-
Aquestive TherapeuticsAfsluttet
-
Karadeniz Technical UniversityAfsluttetPostmenopausale kvinder | Raloxifen